Active iTBS for Anorexia Nervosa

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of California San Diego, San Diego, CA
Anorexia Nervosa+1 More
rTMS treatment using BrainsWay Model 104 system with H1-Coil - Device
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

Anorexia nervosa is a severe psychiatric disorder associated with food avoidance and body image distortion, that is feeling fat despite being underweight. It is the third most common chronic illness among adolescent females, and its mortality reaches its peak between the ages 16 and 29 years old. There are very few treatments for anorexia nervosa and especially no biological treatments have been approved. Recent brain imaging research has repeatedly implicated brain circuits that include the insula in the disorder. The insula is a brain region important in taste processing as well as in the integration of body perception and has strong connections to the brain reward system. Transcranial magnetic stimulation (TMS) is a relatively new methodology that has been shown to alter neurocircuitry and alleviate depression. Here, the study goal is to develop TMS as a methodology to change altered neurocircuitry in anorexia nervosa and alleviate disorder specific behaviors.

Eligible Conditions

  • Anorexia Nervosa

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Anorexia Nervosa

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: at study completion, up to 2 weeks

Week 2
Beck Depression Inventory
Eating Disorders Inventory 3 (EDI-3) Body Dissatisfaction Subscale
Eating Disorders Inventory 3 Drive for Thinness Subscale
Spielberger State-Trait Anxiety Scale-Version Y (STAI-Y) State Anxiety Subscale
Spielberger State-Trait Anxiety Scale-Version Y (STAI-Y) Trait Anxiety Subscale
Week 2
Weight gain
Week 2
Acceptability of TMS procedures
Feasibility of TMS sessions

Trial Safety

Safety Progress

1 of 3

Other trials for Anorexia Nervosa

Trial Design

2 Treatment Groups

Active iTBS
1 of 2
Sham iTBS
1 of 2
Experimental Treatment
Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Active iTBS · Has Placebo Group · N/A

Active iTBS
Device
Experimental Group · 1 Intervention: rTMS treatment using BrainsWay Model 104 system with H1-Coil · Intervention Types: Device
Sham iTBS
Device
ShamComparator Group · 1 Intervention: sham TMS using BrainsWay Model 104 system with H1-Coil · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at study completion, up to 2 weeks

Trial Background

Prof. Guido Frank, Professor
Principal Investigator
University of California, San Diego
Closest Location: University of California San Diego · San Diego, CA
Photo of University of California San Diego  1Photo of University of California San Diego  2Photo of University of California San Diego  3
2003First Recorded Clinical Trial
6 TrialsResearching Anorexia Nervosa
262 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a history of restricting or binge/purge behaviours.
You have a primary language of English.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.